| 肺纤维化的相关分子机制和治疗现状 |
| |
| 引用本文： | 周世琴,骆亚莉,周雯,齐晓风,肖孟勇.肺纤维化的相关分子机制和治疗现状[J].金属学报,2022,27(10):1133-1147. |
| |
| 作者姓名： | 周世琴 骆亚莉 周雯 齐晓风 肖孟勇 |
| |
| 作者单位： | 1.甘肃中医药大学，甘肃省高校重大疾病分子医学与中医药防治研究省级重点实验室，兰州 730000，甘肃；;2.甘肃中医药大学，基础医学院病理教研室，兰州 730000，甘肃 |
| |
| 基金项目： | 甘肃省教育厅创新基金项目（2021A-085）；国家自然科学基金（82160846）；甘肃省创新基地和人才计划自然科学基金（20JR10RA321） |
| |
| 摘 要： | 肺纤维化（pulmonary fibrosisa, PF）是一种慢性进行性间质性肺疾病。PF的发病机制尚未明确，两种被批准用于PF治疗的抗纤维化药物，尼达尼布和吡非尼酮，已被证明可以减少PF的肺功能下降，但均具有副作用，至今尚无明显有效的治疗方法来阻止PF的进展。因此，在本综述中，我们重点关注肺纤维化所涉及的不同细胞，分子机制以及目前正对PF的治疗进展，从而为更好地在PF中理解这些细胞，分子机制及药物开发使用提供理论支持。
|
| 关 键 词： | 肺纤维化 上皮细胞 成纤维细胞 上皮间质转化 巨噬细胞 线粒体 端粒 治疗现状 |
| 收稿时间： | 2022-08-01 |
| 修稿时间： | 2022-10-24 |
Molecular mechanism and treatment of pulmonary fibrosis |
| |
| ZHOU Shiqin,LUO Yali,ZHOU Wen,Qi Xiaofeng,XIAO Mengyong.Molecular mechanism and treatment of pulmonary fibrosis[J].Acta Metallurgica Sinica,2022,27(10):1133-1147. |
| |
| Authors: | ZHOU Shiqin LUO Yali ZHOU Wen Qi Xiaofeng XIAO Mengyong |
| |
| Affiliation: | 1. Provincial Key Laboratory of Molecular Medicine and TCM Prevention and Treatment of Major Diseases in Colleges and Universities of Gansu Province, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, Gansu, China;2. Department of Pathology, College of Basic Medicine, Lanzhou 730000, Gansu, China |
| |
| Abstract: | Pulmonary fibrosis (PF) is a chronic progressive interstitial lung disease. The pathogenesis of PF is not yet clear. The two anti fibrosis drugs approved for IPF treatment, nidanib and pirfenidone, have been proved to reduce the decline of pulmonary function of PF, but both have side effects. So far, there is no obvious and effective treatment to prevent the progress of PF. Therefore, this review focuses on the different cells, molecular mechanisms involved in PF and the current treatment progress of PF, so as to provide theoretical support for a better understanding of these cells, molecular mechanisms and drug development and application in PF. |
| |
| Keywords: | |
|
| 点击此处可从《金属学报》浏览原始摘要信息 |
|
点击此处可从《金属学报》下载全文 |
|
